From evidence to implementation: key priorities for pharmacogenomics-guided treatment and prevention from a European...

Pharmacogenomics holds promise for enhancing drug safety and efficacy, paving the way for more precise, patient-centered therapeutic approaches and supporting personalized medicine and prevention. However, its routine integration into healthcare remains limited. A European multidisciplinary expert workshop was held in Amsterdam in January 2025, to share experiences regarding the priorities to further implement pharmacogenomic-guided treatment and prevention into clinical practice. A qualitative content analysis was conducted to identify key themes to support improved implementation of pharmacogenomics. The analysis drew on inputs from a multi-stakeholder workshop involving 55 participants from 10 European countries, representing policy, healthcare, academia, patient organizations and industry. The paper is centered around three central pillars to implement pharmacogenomics: evidence, acceptance, and integration into healthcare systems. Based on the expert presentations and discussions, five key priorities were identified for advancing pharmacogenomics: 1) the need for robust clinical and health economic evaluations to support funding and reimbursement decisions, 2) education and training for healthcare professionals, and raising awareness of pharmacogenomics among policymakers and the public, 3) investment in information technology and data infrastructure for interoperable storage and clinical decision making, 4) harmonizing regulatory and reimbursement policies, and 5) ensuring equitable access of pharmacogenomics. Findings underscore the need of a closer alignment through e.g. a dedicated network to move pharmacogenomics from an emerging innovation to a standard component of personalized medicine across Europe. Multidisciplinary collaboration throughout the implementation pathway will be crucial to advance pharmacogenomic-guided treatment and prevention as key part of personalized medicine.